First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions Completes First Import Shipment in China, with the First Global Prescription Issued in Beijing on the Same Day
June 5, 2026 First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions Completes First Import Shipment in China, with the First Global Prescription Issued in Beijing on the Same Day
April 24, 2026 Blue Light Cystoscopy System Approved for Marketing in China; “Blue Light Era” for Precision Treatment of Bladder Cancer Begins
April 17, 2026 Asieris Pharmaceuticals Releases 2025 Annual Report：Flagship Product Approval Marks Inflection Point; Commercialization 2.0 Drives Growth
March 25, 2026 Cevira® Endorsed with Level 1A Evidence in Expert Consensus, Establishing a New Benchmark for Non-Invasive Treatment of Cervical Precancerous Lesions
March 24, 2026 Asieris and SPH Kyuan Trade Announce Import and Distribution Strategic Partnership to Accelerate the Commercialization of Cevira®
March 3, 2026 Asieris’ CEVIRA® Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
